Category: Fresenius Medical CareSyndicate content

Fresenius' renal research division gets a makeover

March 26, 2014 by Arezu Sarvestani

Dialysis services provider Fresenius gives its renal research arm a new look, renaming it "Frenova" and reasserting its focus on new product development.

Fresenius forms renal research arm

Dialysis giant Fresenius (NYSE:FMS) re-introduced its renal research branch, renaming it "Frenova" and reiterating the group's commitment to developing novel therapies.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014

March 13, 2014 by MassDevice staff

Here's a look at some of the top Wall Street stories for medical device companies this week.

Biomet announces IPO plans

March 7, 2014 by Brad Perriello

Biomet announces IPO plans

Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.

Siemens, GE named among worst-performing device makers of the year | MassDevice.com On Call

March 12, 2014 by Arezu Sarvestani

QMed releases a list of the 5 worst-performing medical device companies of early 2014, including Siemens, GE and Fresenius, among others.

MassDevice.com On Call

MASSDEVICE ON CALL — Medtech giants have seen Wall Street bumps so far this year, but several of the company's in the industry's top 40 haven't been so fortunate.

NxStage, Fresenius extend System One deal

January 14, 2014 by Chris Walker

Fresenius renews its pact for the purchase of NxStage Medical's System One hemodialysis device.

NxStage, Fresenius extend agreement

Fresenius (NYSE:FMS) and NxStage Medical (NSDQ:NXTM) said they extended a supply deal for NxStage's System One hemodialysis device until 2016.

Legal: Fresenius is off the hook as Baxter fails to recoup $24M infringement decision

November 12, 2013 by Arezu Sarvestani

A Federal Circuit court refuses to re-hear the case after a lower court throws out Baxter's $23.5 million win against Fresenius, which was charged with infringement of hemodialysis patents.

Legal: Fresenius is off the hook as Baxter can't recoup $24M infringement

More legal trouble for Fresenius

August 30, 2013 by Sony Salzman

Legal troubles escalate for German healthcare giant Fresenius, which now faces a class action lawsuit over its dialysis drug GranuFlo.

More legal trouble for Fresenius

Hundreds of lawsuits against Fresenius (NYSE:FMS) escalated into a class action filed in California state court with patients claiming that the German healthcare company intentionally hid serious health risks associated with its dialysis drug GranuFlo.

FDA hits Fresenius with 3rd warning letter this year

August 27, 2013 by Sony Salzman

The FDA hands German healthcare group Fresenius a warning letter over violations cited after an April inspection of a Puerto Rico facility.

FDA hits Fresenius with 3rd warning letter this year

The FDA took issue with certain manufacturing processes at a Fresenius (NYSE:FMS) plant in Puerto Rico, handing the German medical healthcare company its 3rd warning letter this year.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp